Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-κB/cyclin D1 pathway and facilitates tumor growth

Cancer Science

Volumn 99, Issue 5, 2008, Pages 952-957

  Liu, Shou ^a   Tan, Wen Yong ^a,b   Chen, Qiong Rong ^b   Chen, Xiao Ping ^a   Fu, Kang ^a   Zhao, Yan Ying ^a   Chen, Zheng Wang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; AIF1 PROTEIN, HUMAN; DNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BREAST TUMOR; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DNA-BINDING PROTEINS; HUMANS; MICE; MICE, NUDE; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 43649100746     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00787.x     Document Type: Article

References (25)

1. Parkin DM. International variation. Oncogene 2004; 23: 6329-40.
2. Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA. Cancer mortality surveillance -United States, 1990-2000. Morbidity Mortality Weekly Rep 2004; 53: 1-108.
3. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539-45.
4. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-7.
5. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193: 727-39.
6. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355: 248-50.
7. Chen ZW, Ahren B, Ostenson CG et al. Identification, isolation, and characterization of daintain (allograft inflammatory factor 1), a macrophage polypeptide with effects on insulin secretion and abundantly present in the pancreas of prediabetic BB rats. Proc Natl Acad Sci USA 1997; 94: 13879-84.
8. Utans U, Arceci R, Yamashita Y, Russell ME. Cloning and characterization of allograft inflammatory factor-1: A novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest 1995; 95: 2954-62.
9. Deininger MH, Meyermann R, Schluesener HJ. The allograft infammatory factor-1 family of proteins. FEBS Lett 2002; 514: 115-21.
10. Autieri VM, Kelemen S, Thomas BA, Feller ED, Goldman BI, Eisen HJ. Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation 2002; 106: 2218-23.
11. Kimura M, Kawahito Y, Obayashi H et al. A critical role for allograft inflammatory factor-1 in the pathogenesis of rheumatoid arthritis. J Immunol 2007; 178: 3316-22.
12. Orsmark C, Skoog T, Jeskanen L, Kere J, Saarialho-Kere U. Expression of allograft inflammatory factor-1 in inflammatory skin disorders. Acta Derm Venereol 2007; 87: 223-7.
13. Del GF, Maul GG, Jiménez SA, Artlett CM. Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor beta. Arthritis Rheum 2006; 54: 2616-25.
14. Fu K, Zhao YY, Tang WX, Zhong Y, Yang TB, Wang JH. Preparation and identification of monoclonal antibodies against daintain. Hybridoma (Larchmt) 2006; 25: 95-7.
15. Tian Y, Kelemen SE, Autieri MV. Inhibition of AIF-1 expression by constitutive siRNA expression reduces macrophage migration, proliferation, and signal transduction initiated by atherogenic stimuli. Am J Physiol Cell Physiol 2006; 290: 1083-91.
16. Kelemen SE, Autieri MV. Expression of allograft inflammatory factor-1 in T lymphocytes. Am J Pathol 2005; 167: 619-26.
17. Autieri MV, Carbone C, Mu A. Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury. Arterioscler Thromb Vasc Biol 2000; 20: 1737-44.
18. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974; 71: 1286-90.
19. 1 -to-S-phase transition. Mol Cellular Biol 1999; 19: 2690-8.
20. Autieri MV, Carbone CM. Overexpression of allograft inflammatory factor-1 promotes proliferation of vascular smooth muscle cells by cell cycle deregulation. Arterioscler Thromb Vasc Biol 2001;21: 1421-6.
21. Hunter T, Pines J. Cyclins and cancer II. Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-82.
22. Fu MF, Wang CG, Li ZP, Sakamaki T, Pestell RG. Cyclin D1: Normal and abnormal functions. Endocrinology 2004; 145: 5439-47.
23. MARX J. Inflammation and cancer: The link grows stronger. Science 2004; 306: 966-8.
24. Pikarsky E, Porat RM, Stein I et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
25. Diest PJ, Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: A review. J Clin Pathol 2004; 57: 675-81.